251
Views
12
CrossRef citations to date
0
Altmetric
Review

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

&
Pages 461-469 | Published online: 22 May 2020

References

  • Wight J, Paisly S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–435. doi:10.1046/j.1365-2516.2003.00780.x
  • Astermark J, Altisent C, Batorova A, et al. European haemophilia therapy standardisation board non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16(5):747–766. doi:10.1111/j.1365-2516.2010.02231.x
  • Gouw S, van der Berg H, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046–4055. doi:10.1182/blood-2012-09-457036
  • Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia. 2009;16(102):66–70. doi:10.1111/j.1365-2516.2008.01923.x
  • Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005;130(3):422–427. doi:10.1111/j.1365-2141.2005.05605.x
  • Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13(5):606–612. doi:10.1111/j.1365-2516.2007.01518.x
  • Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group. Blood. 2003;102(7):2358–2363. doi:10.1182/blood-2003-03-0941
  • Negrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006;12:4–13.
  • Lindley CM, Sawyer WT, Macik G, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638–648.
  • Young G, Shafer FE, Rojas P, Seremetis S. Single 270 micro kg(−1)-dose rFVIIa vs. Standard 90 micro kg(−1)-dose rFVIIa and aPCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14(2):287–294. doi:10.1111/j.1365-2516.2007.01601.x
  • Brackmann HH, White GC, Berntorp E, Andersen T, Escuriola‐Ettingshausen C. Immune tolerance induction: what have we learned over time? Haemophilia. 2018;24 Suppl 3(Suppl3):3–14. doi:10.1111/hae.13445
  • DiMichele DM. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia. 2009;15(1):320–328. doi:10.1111/j.1365-2516.2008.01880.x
  • Hay CRM, DiMichele DM. The principal results of the international immune tolerance study: a randomized dose comparison. Blood. 2012;119(6):1335–1344. doi:10.1182/blood-2011-08-369132
  • Valentino LA, Kempton CL, Krause-Jarres R, Mathew P, Meeks SL, Reiss UM, International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia. 2015;21(5):559–567. doi:10.1111/hae.12730
  • Rocino A, Cortesi PA, Scalone L, et al. Immune tolerance induction in patients with haemophilia A and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia. 2016;22(1):96–102. doi:10.1111/hae.12780
  • Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost. 2016;14(11):2095–2106. doi:10.1111/jth.13491
  • Castaman G, Linari S. Current and emerging biologics for the treatment of hemophilia. Expert Opin Biol Ther. 2019;19(8):801–810. doi:10.1080/14712598.2019.1614163
  • Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–1574. doi:10.1038/nm.2942
  • Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044–2053. doi:10.1056/NEJMoa1511769
  • Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348–1357. doi:10.1160/TH17-01-0030
  • Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463–2468. doi:10.1182/blood-2017-08-801662
  • U.S. Department of Health and Human Services. Food and Drug Administration. FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. Available from. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585650.htm. Accessed 21 December. 2017
  • Roche. European Commission approve Roche’s Hemlibra for people with hemophilia A with factor VIII inhibitors. Press release. Basel, Switzerland, 2018. Available from: https://www.roche.com/media/store/releases/med-cor-2018-02-27.htm. Accessed 14 May 2018.
  • Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633–1641. doi:10.1182/blood-2015-06-650226
  • Yoneyama K, Schmitt C, Kotani N, et al. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet. 2018;57(9):1123–1134. doi:10.1007/s40262-017-0616-3
  • Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A: results from the HAVEN 1-4 studies. Blood. 2018;132:633.
  • Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P; The members of the French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost. 1997;77(6):1113–1119.
  • Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542–547. doi:10.1046/j.1365-2141.1997.4463256.x
  • Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates FIX and FX on the surface of activated platelets: thoughts on the mechanism of action of high dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9 Suppl 1:S61–S65.
  • Negrier C, Chamouard V, Lienhart A, Nougier C, Fleury R. A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system. Haemophilia. 2019;25(6):1020–1027. doi:10.1111/hae.13863
  • Kavakli K, Makris M, Zulfikar B, et al. Novoseven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen or recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomized, double-blind, cross over trial. Thromb Haemost. 2006;95(4):600–605.
  • Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in haemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367–371.
  • Neufeld EJ, Negrier C, Arkhammar P, et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev. 2015;29(Suppl1):S34–41. doi:10.1016/S0268-960X(15)30006-0
  • Astermark J, Donfield SM, DiMichele DM, et al. FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA novoseven comparative (FENOC) study. Blood. 2007;109(2):546–551. doi:10.1182/blood-2006-04-017988
  • Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia. 2004;10(4):397–400. doi:10.1111/j.1365-2516.2004.00924.x
  • Gringeri A, Fischer K, Karafoulidou A, et al. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia. 2011;17(4):630–635. doi:10.1111/j.1365-2516.2010.02467.x
  • Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis. 1998;9:S115–S118.
  • Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8(2):83–90. doi:10.1046/j.1365-2516.2002.00532.x
  • Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684–1692. doi:10.1056/NEJMoa1104435
  • Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20(1):65–72. doi:10.1111/hae.12246
  • Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904–1913. doi:10.1111/j.1538-7836.2007.02663.x
  • Ljung R. Aspects of prophylactic treatment of hemophilia. Thromb J. 2016;14:S60–63.
  • Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia with inhibitors. N Engl J Med. 2017;377(9):809–818. doi:10.1056/NEJMoa1703068
  • Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127–2138. doi:10.1182/blood.2019001869
  • Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomized phase 3 study. Lancet Haematol. 2019;6(6):e295–e305. doi:10.1016/S2352-3026(19)30054-7
  • Kotani N, Yoneyama K, Katakami N, et al. Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers. Clin Pharmacol Drug Dev. 2018;8(6):702–12. Epub ahead of print.
  • Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO inhibitor working party and executive committee. Haemophilia. 2018;24(3):344–347. doi:10.1111/hae.13495
  • Castaman G, Santoro C, Coppola A, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2019. doi:10.2450/2019/.0186-19
  • Susen S, Gruel Y, Godier A, et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra): proposal from the French network on inherited bleeding disorders (MHEMO), the french reference centre on haemophilia, in collaboration with the french working group on perioperative haemostasis. Haemophilia. 2019;25(5):731–737. doi:10.1111/hae.13817
  • MASAC Document #255, approved on November 21, 2018
  • Agerso H, Brophy DF, Pelzer H, et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost. 2011;9(2):333–338. doi:10.1111/j.1538-7836.2010.04152.x
  • Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the Haven clinical program. J Thromb Haemost. 2019;17(1):1–8. doi:10.1111/jth.14351
  • Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience in two multicenter, open label phase 3 studies of Emicizumab in person with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood. 2017;130:89.
  • Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019;104(8):e380–e382. doi:10.3324/haematol.2018.215129
  • Santagostino E, Oldenburg J, Chang T, et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. Res Pract Haemost. 2019;3(S1):115.
  • Kizilocak H, Yukhtman CL, Marquez-Casas E, et al. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019;10:1–9.
  • Seaman CD, Ragni MV. Emicizumab use in major orthopaedic surgery. Blood Adv. 2019;3(11):1722–1724. doi:10.1182/bloodadvances.2019000228